Last reviewed · How we verify

OMP-54F28, Paclitaxel and Carboplatin

OncoMed Pharmaceuticals, Inc. · Phase 1 active Small molecule

OMP-54F28, Paclitaxel and Carboplatin is a Small molecule drug developed by OncoMed Pharmaceuticals, Inc.. It is currently in Phase 1 development. Also known as: OMP-54F28, Paclitaxel, Carboplatin.

At a glance

Generic nameOMP-54F28, Paclitaxel and Carboplatin
Also known asOMP-54F28, Paclitaxel, Carboplatin
SponsorOncoMed Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OMP-54F28, Paclitaxel and Carboplatin

What is OMP-54F28, Paclitaxel and Carboplatin?

OMP-54F28, Paclitaxel and Carboplatin is a Small molecule drug developed by OncoMed Pharmaceuticals, Inc..

Who makes OMP-54F28, Paclitaxel and Carboplatin?

OMP-54F28, Paclitaxel and Carboplatin is developed by OncoMed Pharmaceuticals, Inc. (see full OncoMed Pharmaceuticals, Inc. pipeline at /company/oncomed-pharmaceuticals-inc).

Is OMP-54F28, Paclitaxel and Carboplatin also known as anything else?

OMP-54F28, Paclitaxel and Carboplatin is also known as OMP-54F28, Paclitaxel, Carboplatin.

What development phase is OMP-54F28, Paclitaxel and Carboplatin in?

OMP-54F28, Paclitaxel and Carboplatin is in Phase 1.

Related